New drug DM002 enters first human tests for Hard-to-Treat cancers
NCT ID NCT06751329
First seen Jan 20, 2026 · Last updated May 19, 2026 · Updated 12 times
Summary
This early-phase study tests a new drug called DM002 in about 160 people with advanced solid tumors (ovarian, prostate, endometrial, colorectal, or other solid cancers). The study has two parts: first, finding a safe dose by giving small groups gradually higher doses; second, giving that dose to more participants to check safety and see if the cancer shrinks or stabilizes. Participants will have regular visits and follow-up calls for up to 30 days after treatment ends.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATIC NEOPLASMS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Cancer Care Wollongong
RECRUITINGWollongong, New South Wales, 2500, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Scientia Clinical Research
RECRUITINGRandwick, New South Wales, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Southern Oncology Clinical Research Unit
RECRUITINGAdelaide, South Australia, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The University of Texas, MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Oklahoma Health Sciences Center
RECRUITINGOklahoma City, Oklahoma, 73190, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.